Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis
暂无分享,去创建一个
G. Raghu | M. Wijsenbeek | R. Baughman | K. Gibson | H. Shigemitsu | E. Barnathan | M. Judson | J. Barney | M. Drent | R. Watt | U. Costabel | N. Hamzeh | C. Brodmerkel | D. Culver | C. Albera | I. Huizar | P. Agarwal
[1] D. Cella,et al. A conceptual model of health-related quality of life in sarcoidosis , 2014, Quality of Life Research.
[2] J. Grutters,et al. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis , 2013, European Respiratory Journal.
[3] R. Pariser,et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. , 2013, Journal of the American Academy of Dermatology.
[4] R. Baughman,et al. Established and experimental medical therapy of pulmonary sarcoidosis , 2013, European Respiratory Journal.
[5] M. Mascelli,et al. Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway. , 2012, Journal of the American Academy of Dermatology.
[6] Prescott G Woodruff,et al. Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. , 2011, American journal of respiratory and critical care medicine.
[7] R. D. du Bois,et al. Inflammatory Profile and Response to Anti-Tumor Necrosis Factor Therapy in Patients with Chronic Pulmonary Sarcoidosis , 2011, Clinical and Vaccine Immunology.
[8] R. Baughman,et al. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. , 2010, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[9] 陶仲为. Sarcoidosis , 2009 .
[10] R. D. du Bois,et al. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. , 2009, Chest.
[11] D. Lackland,et al. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. , 2009, Chest.
[12] R. Baughman,et al. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. , 2008, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[13] G. Raghu,et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial , 2008, European Respiratory Journal.
[14] S. Antoniu. Infliximab for the therapy of chronic sarcoidosis , 2007, Expert opinion on investigational drugs.
[15] R. D. du Bois,et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. , 2006, American journal of respiratory and critical care medicine.
[16] N. Siafakas,et al. Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[17] R. Baughman,et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. , 2005, Chest.
[18] G. V. van Heck,et al. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). , 2004, British journal of health psychology.
[19] A. Fietta,et al. BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis. , 2004, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[20] D. Lison,et al. Characterization of p40 and IL-10 in the BALF of patients with pulmonary sarcoidosis. , 2003, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[21] D. Schroeder,et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. , 2003, Chest.
[22] K. Kamiguchi,et al. Increased circulating interleukin‐12 (IL‐12) p40 in pulmonary sarcoidosis , 2003, Clinical and experimental immunology.
[23] T. Goldmann,et al. Alveolar macrophages are the main source for tumour necrosis factor‐α in patients with sarcoidosis , 2003, European Respiratory Journal.
[24] H. Okamura,et al. IL-12 and IL-18 Are Increased and Stimulate IFN-γ Production in Sarcoid Lungs , 2001, The Journal of Immunology.
[25] N. Sato,et al. Enhanced mRNA expression of Th1 cytokines and IL-12 in active pulmonary sarcoidosis. , 2000, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[26] E. Minshall,et al. Increased expression of IL-12 receptor mRNA in active pulmonary tuberculosis and sarcoidosis. , 1999, American journal of respiratory and critical care medicine.
[27] P. Zabel,et al. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. , 1997, American journal of respiratory and critical care medicine.
[28] M. Riquet,et al. Cytokine patterns in tuberculous and sarcoid granulomas: correlations with histopathologic features of the granulomatous response. , 1997, Journal of immunology.
[29] Z. Yasruel,et al. Cytokine mRNA gene expression in active and nonactive pulmonary sarcoidosis. , 1997, The European respiratory journal.
[30] R. Steiner,et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. , 1997, Chest.
[31] G. Trinchieri,et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. , 1996, Journal of immunology.
[32] J. Roman,et al. Distribution of extracellular matrices, matrix receptors, and transforming growth factor-beta 1 in human and experimental lung granulomatous inflammation. , 1995, The American journal of the medical sciences.
[33] H. Magnussen,et al. Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. , 1993, The Journal of allergy and clinical immunology.
[34] D. Schwartz,et al. The relationship between alveolar macrophage TNF, IL-1, and PGE2 release, alveolitis, and disease severity in sarcoidosis. , 1993, Chest.
[35] C. Sherbourne,et al. The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .
[36] R. Crystal,et al. Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. , 1985, The Journal of clinical investigation.
[37] R. Crystal,et al. Production of fibronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung diseases. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[38] O. Sharma,et al. Cutaneous sarcoidosis: clinical features and management. , 1972, Chest.
[39] R. Baughman,et al. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. , 2014, Respiratory medicine.
[40] R. Baughman. Treatment of sarcoidosis. , 2013, Panminerva medica.
[41] M. Iannuzzi,et al. Tumour Necrosis Factor in Sarcoidosis and its Potential for Targeted Therapy , 2012, BioDrugs.
[42] R. Baughman,et al. Chronic Facial Sarcoidosis Including Lupus Pernio , 2008, American journal of clinical dermatology.
[43] E. Miyazaki,et al. Circulating IL-12 p40 is increased in the patients with sarcoidosis, correlation with clinical markers. , 2007, Internal medicine.
[44] Statement on Sarcoidosis , 1999 .
[45] R. Baughman,et al. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. , 1990, The Journal of laboratory and clinical medicine.
[46] R. Govindarajan,et al. Pulmonary sarcoidosis. , 1985, The Journal of the Association of Physicians of India.